AGI.do

Products

What will AGI do for Atorvastatin sodium?

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H34FN2O5.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DN43058TIV. European Medicines Agency schedules atorvastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35008. Most nations, for tariff and trade purposes, schedule atorvastatin sodium under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN SODIUM remains US FDA's Preferred Term for this commodity. Atorvastatin sodium bears US NLM identifiers UMLS ID C2698196 and NCI Concept Code C78676. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.[NA+].

How AGI delivers it

Four ways AGI delivers for Atorvastatin sodium

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Atorvastatin sodium, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Atorvastatin sodium, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Atorvastatin sodium connects

measured by

  • Active Ingredient Potencymodel
  • Assay Puritymodel
  • Chiral Puritymodel
  • Compound Puritymodel
  • Particle Size Distributionmodel
  • Residual Solventmodel

Go deeper

Explore Atorvastatin sodium

Read the deeper take on agi.asView as markdown